The main biological role of doxorubicin liposomes is to achieve anti-tumor effects by inhibiting the replication of cellular DNA, thereby killing tumor cells. Doxorubicin liposomes are liposomal dosage forms of the anthracycline antitumor drug doxorubicin, in which doxorubicin is encapsulated in polyethylene glycolized liposomes, which increases the lipophilicity of the drug and reduces the cardiotoxic effects, and also extends the time of drug circulation in the blood, i.e., extends the half-life of the drug. Doxorubicin liposomes are a new dosage form with the advantages of less cardiotoxic effects and stronger antitumor effects compared with the original doxorubicin drug, and are widely used in the treatment of leukemia, malignant lymphoma, breast cancer and other malignant tumors.